“My goal is really simple. I want to have the biggest impact on human suffering,” says Lou Reese, co-founder of the biotech company Vaxxinity. He may succeed. If all goes well, by 2030 the company will have a new drug that will revolutionize our treatment of one of the world’s most feared diseases, and perhaps even lead to its eradication.
That disease is Alzheimer’s, the most common form of dementia that causes untold suffering for sufferers and their families. It and other forms of dementia are seen as a ticking time bomb ready to explode in the brains of an increasingly ageing population.
But now there appears to be a way around it. Vaxxinity, based in Cape Canaveral, Florida, is developing vaccines designed to halt the progression of Alzheimer’s or even prevent it from developing in the first place. Several other companies are in on the same game, and the approach shows great promise. “Society is entering an era where the ravages of unchecked Alzheimer’s are no longer inevitable,” says Vaxxinity, a company based in Cape Canaveral, Florida. Dennis Serco At Harvard Medical School.
Around 55 million people are living with dementia, a figure predicted to rise to around 140 million by 2050, with devastating consequences for people with dementia, their families and our health and social care systems. …
